Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18807211 | RECOMBINANT ADENO-ASSOCIATED VIRUS WITH MODIFIED AAV CAPSID POLYPEPTIDES | August 2024 | August 2025 | Allow | 12 | 2 | 1 | No | No |
| 18371636 | FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONE | September 2023 | September 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18137578 | METHOD AND APPARATUS FOR IMPROVED MESENCHYMAL STEM CELL HARVESTING | April 2023 | September 2024 | Allow | 17 | 2 | 0 | No | No |
| 18124921 | NEURAL TISSUE UNIT AND USE OF SUCH A UNIT FOR IMPLANTATION INTO THE NERVOUS SYSTEM OF A MAMMAL | March 2023 | June 2025 | Allow | 27 | 4 | 1 | Yes | No |
| 18157834 | DROPLET TRAPPING STRUCTURE ARRAY, METHOD FOR SPHEROID TRANSFER AND FORMATION OF SPHEROID ARRAY USING THE SAME | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18006163 | Composition for Pluripotent Cell Undifferentiated State Maintenance Culture, Medium for Pluripotent Cell Undifferentiated State Maintenance Culture, Method for Pluripotent Cell Undifferentiated State Maintenance Culture, and Method for Producing Pluripotent Cells | January 2023 | March 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18093860 | A COMPOSITION COMPRISING NICOTINAMIDE MONONUCLEOTIDE AND LEUCOMETHYLENE BLUE | January 2023 | January 2025 | Abandon | 24 | 3 | 1 | Yes | No |
| 18077938 | METHODS OF TREATING CANCER USING NK CELLS | December 2022 | November 2024 | Allow | 23 | 3 | 0 | No | No |
| 17974466 | AAV-VECTORS FOR USE IN GENE THERAPY OF CHOROIDEREMIA | October 2022 | January 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17965257 | CUSTOM AUTOLOGOUS VACCINE COMPOSITION, AND A METHOD FOR ITS MANUFACTURE | October 2022 | March 2025 | Abandon | 29 | 6 | 0 | Yes | No |
| 17956771 | ANIMAL MODEL OF BRAIN TUMOR AND MANUFACTURING METHOD OF ANIMAL MODEL | September 2022 | March 2026 | Allow | 41 | 2 | 0 | Yes | No |
| 17890322 | METHOD OF MAKING A PERSONALIZED BONE GRAFT | August 2022 | March 2026 | Abandon | 43 | 1 | 0 | No | No |
| 17872827 | COMBINATORIAL CANCER IMMUNOTHERAPY | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17869514 | METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS | July 2022 | December 2025 | Allow | 40 | 1 | 0 | No | No |
| 17867881 | COMPOSITIONS AND METHODS FOR REGULATING PRODUCTION OF A FUSION PROTEIN AND RIBONUCLEIC ACID | July 2022 | March 2024 | Allow | 20 | 2 | 1 | Yes | No |
| 17853208 | MESENCHYMAL STEM CELL EXPRESSING HEPATOCYTE GROWTH FACTOR, AND USE THEREOF | June 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17853259 | MESENCHYMAL STEM CELL EXPRESSING TRAIL AND CD, AND USE THEREOF | June 2022 | January 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17841917 | GROWTH MEDIA FOR THREE-DIMENSIONAL CELL CULTURE | June 2022 | September 2025 | Allow | 39 | 1 | 1 | No | No |
| 17735802 | CELL IMMORTALIZATION VIA VORTEX ELECTROPORATION GENE DELIVERY | May 2022 | December 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17661014 | Generation of Cell-Based Products for Human Consumption | April 2022 | March 2025 | Allow | 34 | 5 | 1 | Yes | No |
| 17660165 | METHODS FOR PREPARING A COMESTIBLE MEAT PRODUCT | April 2022 | November 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17660170 | SUBSTRATES FOR PREPARING A COMESTIBLE MEAT PRODUCT | April 2022 | November 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17659589 | BIOPROSTHETIC TISSUE HAVING A REDUCED PROPENSITY FOR IN VIVO CALCIFICATION | April 2022 | September 2025 | Allow | 41 | 1 | 0 | No | No |
| 17762316 | PHYSICAL MANIPULATION OF TISSUE CULTURED TISSUE | March 2022 | September 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17694432 | Additive Manufacturing of Functional Myocardial Tissue | March 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17692530 | Extracellular Matrix-Derived Gels and Related Methods | March 2022 | February 2026 | Allow | 47 | 1 | 0 | Yes | No |
| 17674196 | ENGINEERED ADULT-LIKE HUMAN HEART TISSUE | February 2022 | August 2025 | Allow | 42 | 1 | 0 | No | No |
| 17635978 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF ALPHA-SARCOGLYCAN AND THE TREATMENT OF MUSCULAR DYSTROPHY | February 2022 | June 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17590337 | USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS | February 2022 | November 2023 | Allow | 21 | 1 | 0 | No | No |
| 17581639 | METHODS AND COMPOSITIONS FOR DUAL GLYCAN BINDING AAV2.5 VECTOR | January 2022 | December 2022 | Allow | 11 | 1 | 1 | Yes | No |
| 17572297 | PLANT FAT-BASED SCAFFOLDS FOR THE GROWTH OF CELL-BASED MEATS AND METHODS OF MAKING SUCH PRODUCTS | January 2022 | May 2023 | Allow | 16 | 3 | 0 | Yes | No |
| 17624434 | COMPOSITION FOR PROMOTING PROLIFERATION OF STEM CELLS, CONTAINING, AS ACTIVE INGREDIENT, CP1P OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17557409 | AAV-ABCD1 CONSTRUCTS AND USE FOR TREATMENT OR PREVENTION OF ADRENOLEUKODYSTROPHY (ALD) AND/OR ADRENOMYELONEUROPATHY (AMN) | December 2021 | August 2023 | Allow | 20 | 3 | 1 | Yes | No |
| 17553115 | METHODS FOR PRODUCING ANTIGEN-BINDING PROTEINS AGAINST FOREIGN ANTIGENS | December 2021 | February 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17538206 | COMPOSITIONS AND METHODS FOR PRODUCING GENETICALLY MODIFIED ANIMALS | November 2021 | November 2023 | Allow | 23 | 4 | 1 | Yes | No |
| 17522988 | SINGLE CELLS PLURIPOTENT STEM CELLS IN A SUSPENSION CULTURE | November 2021 | October 2025 | Allow | 48 | 2 | 0 | No | No |
| 17507454 | USE OF NEUROPILIN-1 (NRP1) AS A CELL SURFACE MARKER FOR ISOLATING HUMAN CARDIAC VENTRICULAR PROGENITOR CELLS | October 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17497356 | ORGAN REGENERATION METHOD UTILIZING BLASTOCYST COMPLEMENTATION | October 2021 | October 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17483079 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | September 2021 | September 2025 | Abandon | 48 | 0 | 1 | No | No |
| 17471776 | METHODS AND COMPOSITIONS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS AND RNA-BASED ANTIMICROBIALS | September 2021 | February 2026 | Allow | 53 | 1 | 1 | No | No |
| 17469578 | CRISPR/CPF1 SYSTEMS AND METHODS | September 2021 | September 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17466237 | ADENO-ASSOCIATED VIRUS VECTOR | September 2021 | August 2025 | Abandon | 48 | 4 | 0 | Yes | Yes |
| 17464727 | SCALABLE LENTIVIRAL VECTOR PRODUCTION SYSTEM COMPATIBLE WITH INDUSTRIAL PHARMACEUTICAL APPLICATIONS | September 2021 | November 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17465801 | Engineered Liver Tissues, Arrays Thereof, and Methods of Making the Same | September 2021 | September 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17445282 | NUCLEAR REPROGRAMMING FACTOR AND INDUCED PLURIPOTENT STEM CELLS | August 2021 | July 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17373944 | Use of neuroglobin agonist for preventing or treating mitochondrial RCCI and/or RCCIII deficiency disease | July 2021 | August 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17373523 | Human Pluripotent Stem Cell-Based Models for Predictive Developmental Neural Toxicity | July 2021 | January 2026 | Allow | 55 | 4 | 0 | No | No |
| 17367027 | FUSION PROTEINS COMPRISING PDGF AND VEGF BINDING PORTIONS AND METHODS OF USING THEREOF | July 2021 | July 2025 | Abandon | 48 | 1 | 1 | Yes | No |
| 17304235 | PLANT FAT-BASED SCAFFOLDS FOR THE GROWTH OF CELL-BASED MEATS AND METHODS OF MAKING SUCH PRODUCTS | June 2021 | August 2025 | Allow | 50 | 3 | 0 | Yes | No |
| 17348174 | METHOD FOR INDUCING DIFFERENTIATION OF CORNEAL EPITHELIAL CELLS FROM PLURIPOTENT STEM CELLS | June 2021 | November 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17344064 | METHODS FOR GENERATING AND USING ORGANOIDS AND TISSUE THEREIN | June 2021 | July 2024 | Allow | 37 | 6 | 0 | Yes | No |
| 17340434 | METHOD AND APPARATUS FOR A TISSUE ENGINEERING SYSTEM UTILIZING STACKED LAYERS | June 2021 | January 2026 | Allow | 55 | 1 | 1 | No | No |
| 17298367 | THERAPEUTIC AGENT OF PERIPHERAL BLOOD FLOW DISORDER | May 2021 | December 2025 | Allow | 55 | 4 | 0 | Yes | No |
| 17320388 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | May 2021 | January 2022 | Allow | 8 | 1 | 0 | No | No |
| 17319886 | METHODS OF PREPARING A POLOXAMER FOR USE IN CELL CULTURE MEDIUM | May 2021 | October 2023 | Allow | 30 | 1 | 0 | No | No |
| 17293109 | RECOMBINANT YEAST CELL | May 2021 | April 2025 | Abandon | 47 | 1 | 1 | Yes | No |
| 17317295 | COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY | May 2021 | September 2024 | Abandon | 40 | 4 | 0 | Yes | Yes |
| 17317037 | NON-DECELLULARIZED PLANT LEAF CULTURES FOR MEAT | May 2021 | July 2025 | Allow | 50 | 4 | 1 | Yes | No |
| 17315593 | ISOFORM NELL-1 PEPTIDE | May 2021 | August 2024 | Allow | 39 | 2 | 1 | No | No |
| 17239059 | Synergistic Genome-Nonintegrating Reprogramming by Micrornas and Transcription Factors | April 2021 | September 2023 | Allow | 29 | 1 | 0 | No | No |
| 17227497 | METHODS FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELL | April 2021 | December 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 17219569 | COMBINATORIAL CANCER IMMUNOTHERAPY | March 2021 | March 2022 | Allow | 11 | 2 | 0 | Yes | No |
| 17191378 | TARGETING DNA VACCINES TO B CELLS AS PRIMARY ANTIGEN PRESENTING CELLS | March 2021 | June 2024 | Abandon | 39 | 2 | 0 | No | No |
| 17178127 | TREATMENT OF DISEASES INVOLVING DEFICIENCY OF ENPP1 OR ENPP3 | February 2021 | September 2022 | Abandon | 19 | 2 | 0 | Yes | Yes |
| 17264939 | MODULATION OF mTORCI ACTIVITY AND AUTOPHAGY VIA CIB2-RHEB INTERACTION | February 2021 | February 2026 | Allow | 60 | 4 | 0 | Yes | No |
| 17148324 | NEOEPITOPE VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | January 2021 | December 2021 | Abandon | 12 | 2 | 1 | No | No |
| 17135916 | RXR-ALPHA GENE KNOCKOUT CELL LINE WITH STABLE AND LOW RXR-ALPHA PROTEIN EXPRESSION AND PRODUCTION METHOD THEREOF | December 2020 | November 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17133326 | CORNEAL ENDOTHELIAL CELL MARKER | December 2020 | April 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17131514 | APPARATUSES AND METHODS FOR PREPARING A COMESTIBLE MEAT PRODUCT | December 2020 | March 2022 | Allow | 15 | 3 | 0 | Yes | No |
| 17129706 | ADAM6 MICE | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17129708 | ADAM6 MICE | December 2020 | December 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17253946 | METHODS OF GLYCOENGINEERING PROTEOGLYCANS WITH DISTINCT GLYCAN STRUCTURES | December 2020 | November 2025 | Abandon | 59 | 3 | 1 | No | No |
| 17114888 | REPROGRAMMING PROGENITOR COMPOSITIONS AND METHODS OF USE THEREOF | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17110446 | THREE DIMENSIONAL TISSUE PRINTING DEVICE, THREE DIMENSIONAL TISSUE PRINTING METHOD AND ARTIFICIAL SKIN | December 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17105156 | DIRECTED STEM CELL RECRUITMENT | November 2020 | June 2023 | Allow | 31 | 2 | 0 | No | No |
| 17056710 | SYSTEM OF CELL EXPANSION AND METHODS OF USING THE SAME | November 2020 | January 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17094327 | MESSENGER RNA THERAPY FOR THE TREATMENT OF ORNITHINE TRANSCARBAMYLASE DEFICIENCY | November 2020 | September 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 17094350 | APPARATUS AND METHOD FOR LEVITATIONAL BIOFABRICATION OF ORGAN AND TISSUE ENGINEERED CONSTRUCTS USING TISSUE SPHEROIDS AND MAGNETOACOUSTIC BIFIELD | November 2020 | March 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17081766 | RECOMBINANT ADENO-ASSOCIATED VIRUS-MEDIATED EXPRESSION OF FRACTALKINE FOR TREATMENT OF NEUROINFLAMMATORY AND NEURODEGENERATIVE DISEASES | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17074481 | METHODS AND COMPOSITIONS FOR FEEDER-FREE PLURIPOTENT STEM CELL MEDIA CONTAINING HUMAN SERUM | October 2020 | June 2023 | Allow | 32 | 1 | 0 | No | No |
| 17071627 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | October 2020 | June 2024 | Allow | 44 | 2 | 0 | No | No |
| 17071507 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17071511 | TARGETING THE TUMOR MICROENVIRONMENT USING MANIPULATED NKT CELLS | October 2020 | September 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17046264 | CELL STRUCTURE CONNECTION METHOD AND CONNECTION SUPPORT DEVICE | October 2020 | April 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17063139 | METHOD FOR DIFFERENTIATION INDUCTION IN CULTURED STEM CELLS | October 2020 | May 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 17044947 | POLAND SYNDROME AND METHODS OF TREATMENT | October 2020 | September 2025 | Abandon | 59 | 2 | 1 | No | No |
| 17039407 | BIOLOGICALLY ACTIVE C-TERMINAL ARGININE-CONTAINING PEPTIDES | September 2020 | June 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17039839 | RNA-Guided Endonuclease Expressing Algal Strain for High Efficiency In Vivo Genome Editing | September 2020 | March 2024 | Allow | 42 | 2 | 0 | No | No |
| 17039784 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | September 2020 | June 2025 | Abandon | 57 | 8 | 0 | Yes | No |
| 17044157 | FORMATION OF ARRAYS OF PLANAR INTESTINAL CRYPTS POSSESSING A STEM/PROLIFERATIVE CELL COMPARTMENT AND DIFFERENTIATED CELL ZONE | September 2020 | March 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 17042635 | CARDIOMYOCYTE MATURATION PROMOTER | September 2020 | February 2024 | Allow | 41 | 1 | 0 | No | No |
| 17014113 | PSORIASIS-INDUCED ANIMAL MODEL AND USE THEREOF | September 2020 | December 2023 | Abandon | 39 | 2 | 0 | No | No |
| 17010054 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES | September 2020 | June 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 17001319 | MICROVESICLE AND METHOD FOR PRODUCING THE SAME | August 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16991758 | METHOD FOR RECONSTRUCTING IMMUNE FUNCTION USING PLURIPOTENT STEM CELLS | August 2020 | December 2023 | Allow | 40 | 2 | 0 | Yes | No |
| 16934503 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | July 2020 | April 2021 | Allow | 9 | 1 | 0 | No | No |
| 16913741 | METHOD TO BIOENGINEER DESIGNER RED BLOOD CELLS USING GENE EDITING AND STEM CELL METHODOLOGIES | June 2020 | December 2024 | Abandon | 54 | 3 | 1 | No | No |
| 16958218 | SCAFFOLDING MATERIAL FOR STEM CELL CULTURES AND STEM CELL CULTURE METHOD USING SAME | June 2020 | April 2025 | Allow | 57 | 6 | 0 | Yes | No |
| 16908037 | Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof | June 2020 | July 2023 | Abandon | 37 | 2 | 0 | No | No |
| 16860519 | Functional Targeted Brain Endoskeletonization | April 2020 | October 2022 | Abandon | 30 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MOLOYE, TITILAYO.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MOLOYE, TITILAYO works in Art Unit 1632 and has examined 530 patent applications in our dataset. With an allowance rate of 60.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MOLOYE, TITILAYO's allowance rate of 60.9% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MOLOYE, TITILAYO receive 2.87 office actions before reaching final disposition. This places the examiner in the 83% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by MOLOYE, TITILAYO is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +51.8% benefit to allowance rate for applications examined by MOLOYE, TITILAYO. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 18.1% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 39.2% of cases where such amendments are filed. This entry rate is in the 60% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 82.5% of appeals filed. This is in the 75% percentile among all examiners. Of these withdrawals, 72.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 82.4% are granted (fully or in part). This grant rate is in the 85% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.